GlassScriptPhysician profile
Morium Akthar
NPI 1184941197
$3,368.23
in general payments reported to CMS, 2019-2025
30 companies · $2,253 in 2025
The $2,253 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.96 · 2023: $99.28 · 2024: $988 · 2025: $2,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,250 · Education: $90.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,249.72 |
| Education | $90.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $730.05 | 2024-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $379.78 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Viatris Specialty LLC | $326.54 | 2025 | Yupelri |
| Ucb, INC. | $245.33 | 2023-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $238.71 | 2024-2025 | Tremfya |
| Corcept Therapeutics | $224.54 | 2024-2025 | Korlym |
| Genzyme Corporation | $175.16 | 2025 | |
| Amgen INC. | $99.48 | 2024-2025 | Tezspire, Krystexxa |
| Xeris Pharmaceuticals, INC. | $97.06 | 2024-2025 | Recorlev |
| Lilly USA, LLC | $92.43 | 2024-2025 | Taltz, Zepbound, Jardiance |
| Mylan Specialty L.P. | $88.89 | 2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Alexion Pharmaceuticals, INC. | $78.61 | 2024-2025 | Strensiq |
| Edwards Lifesciences Corporation | $68.36 | 2024 | Pascal |
| Verona Pharma, INC. | $66.96 | 2025 | Ohtuvayre |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $61.76 | 2024-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Alvogen INC | $38.02 | 2025 | Teriparatide |
| Regeneron Healthcare Solutions, INC. | $33.37 | 2025 | Dupixent |
| Ani Pharmaceuticals, INC. | $31.84 | 2024 | Purified Cortrophin Gel |
| Electromed, INC. | $30.03 | 2025 | Smartvest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.58 | 2025 | |
| Baxter Healthcare | $20.86 | 2025 | Hillrom - Monarch Airway Clearance System |
| Qol Medical, LLC | $20.80 | 2023 | Sucraid |
| Kyowa Kirin, INC. | $19.56 | 2025 | |
| Ionis Pharmaceuticals, INC. | $16.74 | 2025 | Tryngolza |
| Merck Sharp & Dohme LLC | $16.30 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.05 | 2025 | Entyvio |
| Averitas Pharma INC. | $15.58 | 2025 | Qutenza |
| Embecta Corp. | $14.08 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Insmed, INC. | $13.77 | 2025 | Arikayce |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morium Akthar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.